Trade Report: The Esperion Therapeutics Inc. (ESPR) PT Raised to $0.00 at Credit Suisse Group AG

The Esperion Therapeutics Inc. (ESPR) PT Raised to $0.00 at Credit Suisse Group AG

Esperion Therapeutics Inc. (NASDAQ:ESPR) had its target price lifted by Credit Suisse Group AG in a report released on Friday. The brokerage currently has an “underperform” rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the stock. Citigroup Inc. restated a “buy” rating and set a $22.00 price target (down from $36.00) on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. Lake Street Capital lowered their price target on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, June 29th. JMP Securities restated a “buy” rating and set a $67.00 price target on shares of Esperion Therapeutics in a research report on Thursday, June 16th. Vetr lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 price target on the stock. in a research report on Monday, July 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $25.00 price target (down from $77.00) on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $28.54.

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded down 6.92% during trading on Friday, reaching $12.11. 323,449 shares of the company’s stock were exchanged. The stock’s market cap is $273.08 million. The company has a 50 day moving average of $12.29 and a 200 day moving average of $13.98. Esperion Therapeutics has a 12-month low of $9.58 and a 12-month high of $30.41.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.16. During the same quarter last year, the business earned ($0.55) EPS. Equities research analysts anticipate that Esperion Therapeutics will post ($3.37) EPS for the current year.

A number of large investors have recently made changes to their positions in the company. Quantitative Investment Management LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter valued at $111,000. Advisor Group Inc. acquired a new stake in shares of Esperion Therapeutics during the second quarter valued at $140,000. Stifel Financial Corp increased its stake in shares of Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 1,438 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 3,657 shares during the last quarter. Finally, ProShare Advisors LLC increased its stake in shares of Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 238 shares during the last quarter. 65.22% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Related posts

Leave a Comment